Share This Profile
Share this profile on Facebook.
Link to this profile on LinkedIn.
Tweet this profile on Twitter.
Email a link to this profile.
See other services through which you can share this profile.
This profile was last updated on 1/6/16  and contains information from public web pages and contributions from the ZoomInfo community.

Dr. Scott A. Siegel Ph.D.

Wrong Dr. Scott A. Siegel Ph.D.?

Vice President Business Developme...

Phone: (908) ***-**** ext. ***  
Institute for Life Science Entrepreneurship
1000 Morris Ave STEm Bldg.
Union , New Jersey 07083
United States

Company Description: ILSE is an independent non-profit translational research institute founded in 2014. The Institute's mission is to identify and advance early life science innovation...   more
Background

Employment History

Board Memberships and Affiliations

  • Founder
    Milestone Life Sciences

Education

  • PhD
  • MBA , communications
    Wharton School
  • Ph.D. , Biochemistry
    SUNY
  • Yale University School of Medicine
45 Total References
Web References
Scott A. Siegel, ...
www.ilsebio.com, 6 July 2015 [cached]
Scott A. Siegel, PhD VP Business Development
...
Dr. Scott Siegel brings over 25 years of experience in the biotechnology and pharmaceutical industries and academia to his role at ILSE. He founded Milestone Life Sciences, a consultancy to biotech and pharma companies in strategy, business development and transactions, and currently also serves as a Lecturer in the MBA communications program at the Wharton School. Dr. Siegel was previously COO and VP, Business Development for Ezose Sciences, a Japan-owned "omics" start-up where he built and then led operations, completing transactions across 3 continents. Prior to that he was VP, Corporate Development for Redpoint Bio, a microcap public biotech with unique technology in taste science and diabetes. Dr. Siegel previously spent eight years with Johnson & Johnson in New Business Development and WW Strategic Marketing. His responsibilities spanned scientific and commercial scouting, assessment and alliances across a breadth of technology and product in-licensing opportunities. Prior to J&J he served in various R&D roles including Senior Director, Preclinical R&D for the start-up Phytera, Inc., Associate Director, Immunobiology for Centocor, Inc. and Section Leader, Immunodiagnostics for Becton Dickinson and Co. Dr. Siegel previously also served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania and Executive-in-Residence for the NYU Office of Industrial Liaison and Tech. Transfer.
Dr. Siegel earned his Ph.D. in Biochemistry from SUNY, Downstate Medical Center and completed postdoctoral studies in Pharmacology at the Yale University School of Medicine. He has over 60 publications and patents and has contributed to the development of 3 launched products, including co-inventor of Remicade®, a blockbuster anti-TNF therapy that to-date has been used to treat over 2 million patients with autoimmune disorders.
Ezose Sciences Inc.
www.ezosesciences.com, 8 July 2013 [cached]
Scott A. Siegel, Ph.D. Chief Operating Officer
Dr. Scott Siegel serves as Ezose Sciences' Chief Operating Officer and head of Business Development, bringing over 25 years experience in the biotechnology and pharmaceutical industries to the role. Prior to joining Ezose he was Vice President of Corporate Development for Redpoint Bio, a publically traded biotechnology company based in NJ. Previously, he spent eight years with Johnson & Johnson in both New Business Development and Worldwide Strategic Marketing, with responsibilities for the in-licensing of new pharmaceutical products and technologies. Earlier in his career he served in various R&D capacities including Senior Director, Preclinical Research and Development for Phytera, Inc.; Associate Director, Immunobiology Research for Centocor, Inc.; and Section Leader, Immunodiagnostics Development for Becton Dickinson and Co. He also previously served as Adjunct Associate Professor of Microbiology at the University of Pennsylvania. Dr. Siegel is one of the inventors of Remicade® (Infliximab), a therapy for rheumatoid arthritis and other inflammatory disorders. He earned his Ph.D. in Biochemistry from the State University of New York, Downstate Medical Center, and completed his postdoctoral studies in the Department of Pharmacology at Yale University School of Medicine.
Company News- October 1, 2007 Redpoint ...
biotechshcom.stockgroup.com, 1 Oct 2007 [cached]
Company News- October 1, 2007 Redpoint Bio Names Scott Siegel, Ph.D. as Vice President of Corporate Development
Redpoint Bio Corporation (OTCBB: RPBC), a company developing compounds to improve the taste of pharmaceutical, food and beverage products, announced earlier today the appointment of Scott A. Siegel, Ph.D., to the position of Vice President of Corporate Development.In his new role, Dr. Siegel will be responsible for the Company's business development strategy and execution and will report directly to Dr. Ray Salemme, Chief Executive Officer.
...
Commenting on today's news, Dr. Salemme noted, "We are delighted to welcome Scott to Redpoint in this key position.
...
With over 20 years of commercial, business development, and research and development expertise with a broad array of life sciences companies, Scott brings to Redpoint a truly well-rounded set of capabilities.We intend to leverage all of these as we move forward aggressively with product development and additional partnership opportunities for our taste enhancer and bitter blocker programs."Prior to joining Redpoint Bio, Dr. Siegel, 50, spent eight years with Johnson & Johnson, most recently as Worldwide Strategic Marketing New Business Development Director, with responsibility for commercial review of global oncology therapeutics licensing opportunities.In this capacity, he lead the establishment of a worldwide business case for deals by creating and leading cross-functional assessment teams consisting of Johnson & Johnson affiliates located across the globe.
Before that, Dr. Siegel served in various positions, including Executive Director, New Business Development and Senior Director, at Ortho Biotech Products, L.P., also a Johnson & Johnson affiliate.While there, Dr. Siegel was responsible for new business development strategy and technology assessment with a focus in the areas of drug delivery and lifecycle management, among others.While at Ortho Biotech he lead or played a key role in the transaction and execution of several licensing agreements with US and international business partners.
Earlier in his career, Dr. Siegel served as Senior Director, Preclinical Research and Product Development for Phytera, Inc.; Associate Director, Immunobiology Research and Development for Centocor, Inc., and; Section Leader, Immunodiagnostics Department at Becton Dickinson and Company.He also served, from 1988 to 1995, as Adjunct Associate Professor of Microbiology at the University of Pennsylvania, School of Dental Medicine.
Dr. Siegel earned his Bachelor of Science degree from the State University of New York, College at New Paltz, where he majored in biology.Dr. Siegel also earned a Ph.D. in biochemistry from the State University of New York, Downstate Medical Center and completed his postdoctoral studies in the Department of Pharmacology at Yale University School of Medicine.
Dr. Siegel is a co-inventor of Remicade , a drug used to treat autoimmune disorders.He is the author of more than 30 scientific and business abstracts and publications, holds 12 issued patents and is a frequent speaker and panel moderator on issues relating to drug delivery, business development and business strategy for the Pharmaceutical and Biotechnology industries.
Scott A. Siegel, PhD ...
www.ilsebio.com, 6 July 2015 [cached]
Scott A. Siegel, PhD
Pictured (left to right): Scott A. ...
www.ilsebio.com, 11 May 2015 [cached]
Pictured (left to right): Scott A. Siegel, Ph.D., VP Business Development, ILSE; Raymond H. Cypess, DVM, Ph.D., Chairman and CEO, ATCC; Keith A. Bostian, Ph.D., Interim CEO, ILSE; Ralph Koch, CPA, Senior Vice President of Finance and Administration/Chief Financial Officer, ATCC; Mindy Goldsborough, Ph.D., Vice President/General Manager,?ATCC Cell Systems; Maryellen de Mars, Ph.D., Senior Director, Standards Resource Center, ATCC; Michael P. Graziano, Ph.D., VP Research, ILSE.
...
For information, contact Scott Siegel, Ph.D. at (908) 737-1922 x104 or ssiegel@ilsebio.com.
Accelerate your business with the industry's most comprehensive profiles on business people and companies.
Find business contacts by city, industry and title. Our B2B directory has just-verified and in-depth profiles, plus the market's top tools for searching, targeting and tracking.
Atlanta | Boston | Chicago | Houston | Los Angeles | New York
Browse ZoomInfo's business people directory. Our professional profiles include verified contact information, biography, work history, affiliations and more.
Browse ZoomInfo's company directory. Our company profiles include corporate background information, detailed descriptions, and links to comprehensive employee profiles with verified contact information.
zirhbt201304